Antitumor Efficacy and Immunomodulation of H‑Ferritin Nanocaged Doxorubicin for Triple Negative Breast Cancer.

ABSTRACT: Triple-negative breast cancer (TNBC) remains a major therapeutic challenge due to its aggressiveness and lack of targeted treatment options. Ferritin-encapsulated doxorubicin (HFn-Dox) is a nanocarrier-based formulation with documented tumor targeting activity and antitumor potential. In this study, we advance its clinical relevance by evaluating the HFn-Dox efficacy and toxicity profile at therapeutic dosing in patient-derived xenograft (PDX) and syngeneic TNBC models. HFn-Dox significantly outperformed free Dox by suppressing tumor growth and reducing metastatic spreading in both the models. When compared with free Dox and the clinically approved pegylated liposomal doxorubicin (Lipo-Dox), HFn-Dox also displayed a more favorable cardiotoxicity profile, which allowed dose intensification

SUBMITTER: Truffi M 

PROVIDER: S-EPMC12834160 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature